ALS drug trial halted: ARGX-119 fails to show promise

NCT ID NCT06441682

Ongoing Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ARGX-119 in 60 adults with ALS. The goal was to see if it was safe and could help with muscle function. The trial was stopped early because early results showed it was unlikely to make a meaningful difference. No safety concerns triggered the stop, but the drug did not appear effective enough to continue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARGX-119 (an experimental biologic drug given by IV infusion)
What this could lead to: If it had worked, this could have pointed toward a treatment to slow muscle decline in ALS. However, the study was stopped early because it was unlikely to show a meaningful benefit.
What could go wrong: This trial was stopped early because early data suggested it would not help patients. The drug is still experimental, and even if safe, it may not improve muscle function or slow the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Aarhus Universitets Hospital

Aarhus, 8200, Denmark
Akademiskt specialistcentrum Karolinska Institutet

Stockholm, 113 61, Sweden
Bispebjerg University Hospital

Copenhagen, 2400, Denmark
CHU Bretonneau

Tours, 37000, France
Hôpital La Pitié Salpêtrière

Paris, 75013, France
Kaye Edmonton Clinic

Edmonton, 11400, Canada
Montreal Neurological Institute and Hospital

Montreal, H3A 2B4, Canada
UMC Utrecht

Utrecht, 3584 CX, Netherlands
UZ Leuven

Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.